PMID- 25065566
OWN - NLM
STAT- MEDLINE
DCOM- 20150522
LR  - 20220317
IS  - 1938-0666 (Electronic)
IS  - 1526-8209 (Linking)
VI  - 14
IP  - 5
DP  - 2014 Oct
TI  - Adverse event management of mTOR inhibitors during treatment of hormone 
      receptor-positive advanced breast cancer: considerations for oncologists.
PG  - 297-308
LID - S1526-8209(14)00084-6 [pii]
LID - 10.1016/j.clbc.2014.03.002 [doi]
AB  - Breast cancer (BC) is diagnosed in nearly 1 in 3 women with cancer in the United 
      States; one third of these patients have regional lymph node metastases at the 
      time of diagnosis. The 5-year survival rate of patients with metastatic BC is 
      very low, and approximately 40,000 women were expected to die of the disease in 
      2013. About 75% of patients with BC have hormone receptor-positive (HR(+)) 
      disease, which is often managed with endocrine therapy; however, most patients 
      eventually have resistance to these therapies. Recently, the mammalian target of 
      rapamycin (mTOR) inhibitor everolimus, in combination with exemestane, improved 
      progression-free survival (PFS) of patients with advanced BC, leading to its 
      approval by the US Food and Drug Administration. Because adverse events (AEs) 
      associated with everolimus might differ from AEs that oncologists who treat 
      patients with BC are more familiar with, everolimus AEs and their effective 
      management are reviewed in this article. Possible dose adjustments of everolimus 
      for patients with renal or hepatic impairment and strategies for minimizing 
      potential interactions of everolimus with other drugs and food are also 
      discussed.
CI  - Copyright (c) 2014 Elsevier Inc. All rights reserved.
FAU - Yardley, Denise A
AU  - Yardley DA
AD  - Sarah Cannon Research Institute, Nashville, TN. Electronic address: 
      dyardley@tnonc.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140604
PL  - United States
TA  - Clin Breast Cancer
JT  - Clinical breast cancer
JID - 100898731
RN  - 0 (Antineoplastic Agents)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Antineoplastic Agents/*adverse effects
MH  - Breast Neoplasms/*drug therapy
MH  - Everolimus
MH  - Female
MH  - Humans
MH  - Medical Oncology
MH  - Sirolimus/adverse effects/*analogs & derivatives
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors
OTO - NOTNLM
OT  - Advanced breast cancer
OT  - Adverse events
OT  - Everolimus
OT  - Infection
OT  - Noninfectious pneumonitis
OT  - Rash
OT  - Stomatitis
OT  - mTOR
EDAT- 2014/07/30 06:00
MHDA- 2015/05/23 06:00
CRDT- 2014/07/29 06:00
PHST- 2013/11/26 00:00 [received]
PHST- 2014/03/06 00:00 [revised]
PHST- 2014/03/24 00:00 [accepted]
PHST- 2014/07/29 06:00 [entrez]
PHST- 2014/07/30 06:00 [pubmed]
PHST- 2015/05/23 06:00 [medline]
AID - S1526-8209(14)00084-6 [pii]
AID - 10.1016/j.clbc.2014.03.002 [doi]
PST - ppublish
SO  - Clin Breast Cancer. 2014 Oct;14(5):297-308. doi: 10.1016/j.clbc.2014.03.002. Epub 
      2014 Jun 4.